Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Viking Global and aTyr Pharma Inc (LIFE)

aTyr Pharma Inc (NASDAQ:LIFE): Andreas Halvorsen’s Viking Global filed an amended 13D.

You can check out Viking Global’s latest holdings and filings here.

Please follow Viking Global (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Viking Global or update its stock holdings.

Andreas Halvorsen
Andreas Halvorsen
Viking Global

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Viking Global Investors 0 2,932,229 0 2,932,229 2,932,229 9.5%
Viking Global Opportunities GP 0 2,932,229 0 2,932,229 2,932,229 9.5%
Viking Global Opportunities Portfolio GP 0 2,932,229 0 2,932,229 2,932,229 9.5%
Viking Global Opportunities Illiquid Investments Sub-Master 0 2,932,229 0 2,932,229 2,932,229 9.5%
O. Andreas Halvorsen 0 2,932,229 0 2,932,229 2,932,229 9.5%
David C. Ott 0 2,932,229 0 2,932,229 2,932,229 9.5%
Rose S. Shabet 0 2,932,229 0 2,932,229 2,932,229 9.5%
Andreas Halvorsen
Andreas Halvorsen
Viking Global

Page 1 of 14 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________

Schedule 13G
________________

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934*

aTyr Pharma, Inc.
(Name of Issuer)

Common stock, par value $0.001 per share
(Title of Class of Securities)

002120103
(CUSIP Number)

August 31, 2017
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)

___________

* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 2 of 14 – SEC Filing

Schedule 13G PAGE 2 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Investors LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 3 of 14 – SEC Filing

Schedule 13G PAGE 3 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 4 of 14 – SEC Filing

Schedule 13G PAGE 4 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Portfolio GP LLC
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
OO
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 5 of 14 – SEC Filing

Schedule 13G PAGE 5 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Viking Global Opportunities Illiquid Investments Sub-Master LP
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
PN
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 6 of 14 – SEC Filing

Schedule 13G PAGE 6 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
O. Andreas Halvorsen
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________
(3) SEC USE ONLY

_____________________________________________________________________________
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Norway
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 7 of 14 – SEC Filing

Schedule 13G PAGE 7 of 14

CUSIP No. 002120103
_____________________________________________________________________________

(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
David C. Ott
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 8 of 14 – SEC Filing

Schedule 13G PAGE 8 of 14

CUSIP No. 002120103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Rose S. Shabet
_____________________________________________________________________________

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [x]
_____________________________________________________________________________

(3) SEC USE ONLY
_____________________________________________________________________________

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________

NUMBER OF (5) SOLE VOTING POWER
0
SHARES ______________________________________________________________

BENEFICIALLY (6) SHARED VOTING POWER
2,932,229*
OWNED BY ______________________________________________________________

EACH (7) SOLE DISPOSITIVE POWER
0
REPORTING ______________________________________________________________

PERSON WITH (8) SHARED DISPOSITIVE POWER
2,932,229*
_____________________________________________________________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
2,932,229*
_____________________________________________________________________________
(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES [x]
_____________________________________________________________________________
(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)
9.5%*
_____________________________________________________________________________
(12) TYPE OF REPORTING PERSON
IN
_____________________________________________________________________________

*See Item 4

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 9 of 14 – SEC Filing

Schedule 13G PAGE 9 of 14

CUSIP No. 002120103

ITEM 1(a). NAME OF ISSUER:
aTyr Pharma, Inc.

ITEM 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
3545 John Hopkins Court, Suite #250
San Diego, California 92121

ITEM 2(a). NAME OF PERSON FILING:
Viking Global Investors LP (“VGI”),
Viking Global Opportunities GP LLC (“Opportunities GP”),
Viking Global Opportunities Portfolio GP LLC
(“Opportunities Portfolio GP”),
Viking Global Opportunities Illiquid Investments Sub-Master LP
(“Opportunities Fund”),
O. Andreas Halvorsen, David C. Ott and
Rose S. Shabet (collectively, the “Reporting Persons”)

ITEM 2(b). ADDRESS OF PRINCIPAL OFFICE OR, IF NONE, RESIDENCE:
The business address of each of the Reporting Persons is
55 Railroad Avenue, Greenwich, Connecticut 06830.

ITEM 2(c). CITIZENSHIP:
VGI is a Delaware limited partnership; Opportunities GP and
Opportunities Portfolio GP are Delaware limited
liability companies; and Opportunities Fund is a Cayman Islands
exempted limited partnership.
O. Andreas Halvorsen is a citizen of Norway.
David C. Ott and Rose S. Shabet are citizens of
the United States.

ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common stock, par value $0.001 per share (“Common Stock”)

ITEM 2(e). CUSIP NUMBER: 002120103

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c),
CHECK WHETHER THE PERSON FILING IS A:

(a) [ ] Broker or dealer registered under Section 15 of the
Act

(b) [ ] Bank as defined in Section 3(a)(6) of the Act

(c) [ ] Insurance Company as defined in Section 3(a)(19) of
the Act

(d) [ ] Investment Company registered under Section 8 of the
Investment Company Act of 1940

(e) [ ] Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940: see Rule 13d-
1(b)(1)(ii)(E)

(f) [ ] Employee Benefit Plan, Pension Fund which is subject
to the provisions of the Employee Retirement Income
Security Act of 1974 or Endowment Fund; see Rule 13d-
1(b)(1)(ii)(F)

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 10 of 14 – SEC Filing

Schedule 13G PAGE 10 of 14

CUSIP No. 002120103

(g) [ ] Parent Holding Company, in accordance with Rule 13d-
1(b)(ii)(G)

(h) [ ] Savings Associations as defined in Section 3(b) of the
Federal Deposit Insurance Act

(i) [ ] Church Plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the
Investment Company Act of 1940

(j) [ ] A non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J)

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with
Rule 240.13d-1(b)(1)(ii)(J), please specify
the type of institution:

ITEM 4. OWNERSHIP.

A. VGI
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

VGI provides managerial services to Opportunities Fund.
VGI has the authority to dispose of and vote the shares
of Common Stock.

Based on Rule 13d-3 of the Securities Exchange Act of 1934,
as amended (the “Act”), VGI may be deemed to beneficially
own the shares of Common Stock directly held by Opportunities Fund.
VGI does not directly own any shares of Common Stock.

VGI beneficially owns 2,932,229 shares of Common Stock
consisting of (i) 1,777,784 shares of Common Stock directly
and beneficially owned by Opportunities Fund and
(ii) 1,154,445 shares of Common Stock underlying
Class X Preferred Stock, par value $0.001 per share
(the “Preferred Stock”) directly and beneficially owned by
Opportunities Fund.

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 11 of 14 – SEC Filing

Schedule 13G PAGE 11 of 14

CUSIP No. 002120103

B. Opportunities GP
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

Opportunities GP serves as the sole member of Opportunities
Portfolio GP and has the authority to dispose of and vote the
shares of Common Stock controlled by Opportunities Portfolio GP,
which consists of the shares of Common Stock directly held by
Opportunities Fund. Opportunities GP does not directly own
any shares of Common Stock.

Based on Rule 13d-3 of the Act, Opportunities GP may be
deemed to beneficially own the shares of Common Stock
controlled by Opportunities Portfolio GP, which consists of
the shares of Common Stock directly held by Opportunities Fund.

Opportunities GP beneficially owns 2,932,229 shares of Common Stock
consisting of (i) 1,777,784 shares of Common Stock directly
and beneficially owned by Opportunities Fund and
(ii) 1,154,445 shares of Common Stock underlying the Preferred Stock
directly and beneficially owned by Opportunities Fund.

C. Opportunities Portfolio GP
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

Opportunities Portfolio GP serves as the general partner of
Opportunities Fund and has the authority to dispose of and vote
the shares of Common Stock directly owned by Opportunities Fund.
Opportunities Portfolio GP does not directly own any shares of
Common Stock.

Based on Rule 13d-3 of the Act, Opportunities Portfolio GP
may be deemed to beneficially own the shares of Common Stock
directly held by Opportunities Fund.

Opportunities Portfolio GP beneficially owns 2,932,229 shares
of Common Stock consisting of (i) 1,777,784 shares of Common Stock
directly and beneficially owned by Opportunities Fund and
(ii) 1,154,445 shares of Common Stock underlying the Preferred Stock
directly and beneficially owned by Opportunities Fund.

D. Opportunities Fund
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

Opportunities Fund has the authority to dispose of and vote the
shares of Common Stock directly owned by it, which power may
be exercised by its general partner, Opportunities Portfolio GP,
and by VGI, an affiliate of Opportunities Portfolio GP, which provides
managerial services to Opportunities Fund. Viking Global Opportunities LP
(a Delaware limited partnership) and Viking Global Opportunities III LP
(a Cayman Islands exempted limited partnership), through its investment
in Viking Global Opportunities Intermediate LP (a Cayman Islands
exempted limited partnership), invest substantially all of their
assets in Viking Global Opportunities Master LP (a Cayman Islands
exempted limited partnership), which in turn invests through
Opportunities Fund.

Opportunities Fund directly and beneficially owns 2,932,229 shares
of Common Stock consisting of (i) 1,777,784 shares of Common Stock
and (ii) 1,154,445 shares of Common Stock underlying the Preferred Stock.

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 12 of 14 – SEC Filing

Schedule 13G PAGE 12 of 14

CUSIP No. 002120103

E. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet
(a) Amount beneficially owned: 2,932,229
(b) Percent of class: 9.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote
0
(ii) shared power to vote or to direct the vote
2,932,229
(iii) sole power to dispose or to direct the disposition
of 0
(iv) shared power to dispose or to direct the disposition
of 2,932,229

Mr. Halvorsen, Mr. Ott and Ms. Shabet, as
Executive Committee Members of Viking Global Partners LLC (“VGPL”),
general partner of VGI and Opportunities GP,
have shared authority to dispose of and vote the shares of
Common Stock beneficially owned by VGI and Opportunities GP.
None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly
owns any shares of Common Stock.

Based on Rule 13d-3 of the Act, each may be deemed to beneficially
own the shares of Common Stock directly held by Opportunities Fund.

Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own
2,932,229 shares of Common Stock consisting of (i) 1,777,784 shares
of Common Stock directly and beneficially owned by Opportunities Fund
and (ii) 1,154,445 shares of Common Stock underlying the Preferred Stock
directly and beneficially owned by Opportunities Fund.

Excluded from each Reporting Person’s beneficial ownership are
(i) 10,275,315 shares of Common Stock issuable upon the conversion of shares
of Preferred Stock directly owned by Opportunities Fund and
(ii) 4,952,829 shares of Common Stock issuable upon the exercise of warrants
directly owned by Opportunities Fund due to a conversion cap that precludes
Opportunities Fund from converting shares of Preferred Stock and
exercising such warrants to the extent that Opportunities Fund would,
after such conversion or exercise, beneficially own (as determined
in accordance with Section 13(d) of the Act) in excess of 9.5% of the shares
of Common Stock outstanding (the “Beneficial Ownership Limitation”).

The percentage of the class of Common Stock beneficially owned by each
Reporting Person is calculated based upon (i) 23,839,007 shares of Common Stock
issued and outstanding as of August 4, 2017, as reported the Issuer in its
quarterly report on Form 10-Q filed with the Securities and Exchange Commission
(the “Commission”) on August 14, 2017, (ii) 5,872,120 shares of Common Stock
issued by the Issuer on or about August 31, 2017, as reported by the Issuer
in its current report on Form 8-K filed with the Commission on August 28, 2017
and (iii) the 1,154,445 shares of Common Stock underlying shares of
Preferred Stock that could be converted by Opportunities Fund without
violating the Beneficial Ownership Limitation.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the
date hereof the Reporting Persons has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following.[]

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Yes, see Item 4.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))
By signing below each Reporting Person certifies that, to the best
of its knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and not held in connection with or as a
participant in any transaction having that purpose or effect.

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 13 of 14 – SEC Filing

Schedule 13G PAGE 13 of 14

CUSIP No. 002120103

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.

DATED: September 8, 2017

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ ROSE S. SHABET
By: Rose S. Shabet – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

Follow Atyr Pharma Inc
Trade (LIFE) Now!

Page 14 of 14 – SEC Filing

Schedule 13G PAGE 14 of 14

CUSIP No. 002120103

EXHIBIT A – JOINT FILING AGREEMENT

This joint filing agreement is made and entered into as of
this 8th day of September, 2017, by and among Viking Global Investors LP,
Viking Global Opportunities GP LLC, Viking Global Opportunities
Portfolio GP LLC, Viking Global Opportunities Illiquid Investments
Sub-Master LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.

The parties hereby agree to jointly prepare and file a Schedule 13G
with respect to aTyr Pharma, Inc., as well as any amendments thereto,
pursuant to the Securities Exchange Act of 1934, as amended.

IN WITNESS WHEREOF, the parties hereto have executed this agreement
as of the date first set forth above.

Dated: September 8, 2017

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

/s/ ROSE S. SHABET
By: Rose S. Shabet – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP, and as
an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC and
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

Follow Atyr Pharma Inc
Trade (LIFE) Now!